- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00360906
Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with relapsing-remitting multiple sclerosis with evidence of disease activity defined as at least one relapse or at least one new MRI lesion during the year prior to inclusion will be included in the study.
Eligible patients will be randomised for daily treatment with either oral omega-3 fatty acid (Triomar™) or placebo. After six months all patients will in addition receive interferon-beta 1a (Rebif™) 44 mcg subcutaneous three times per week for another 18 months.
The patients will undergo monthly contrast enhanced MRI for the first nine months and thereafter at months 12 and 24. They will also be examined by clinical and laboratory tests at six months intervals in addition to month 9 (3 months after start of IFNB treatment). Fatigue and QoL registration will be performed at baseline and at months 6, 12 and 24. Tests for circulating neutralising antibodies against interferon-beta will be performed during the study.
Study Type
Enrollment
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bergen, Norway, N-5021
- Department of Neurology, Haukeland University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient may be included if he/she;
- Is aged between 18 and 55 years (both included).
- Has multiple sclerosis according to the McDonald criteria (McDonald 2001)
- Has a stable disease during the last month period prior to inclusion, and a disability equivalent to EDSS of 5.5 or less (Kurtzke 1983).
- Has shown disease activity defined as at least one relapse or at least one new MRI lesion (T1 enhancing or T2 lesion - ref. McDonald criteria) during the year prior to inclusion.
- Is prepared to and considered able to follow the protocol and to attend the planned visits during the whole study period.
- Is using adequate contraceptive methods and has negative pregnancy test results (female of childbearing potential must).
- Has given written informed consent.
Exclusion Criteria:
A patient has to be excluded if he/she;
- Has received continuous for more than one-week treatment with unsaturated fatty acids (omega-3) within 3 months prior to inclusion in the study.
- Has an active RRMS disease that would strongly be recommended for standard immunomodulatory treatment by the treating neurologist.
- Has received treatment with interferon-beta or glatiramer acetate within 6 months prior to inclusion in the study.
- Has received treatment with lymphoid irradiation, mitoxantrone, cyclophosphamide or long-term glucocorticoids.
- Has received treatment with azathioprine, cyclosporine or other immunosuppressive agents within the year prior to inclusion in the study.
- Has received treatment with glucocorticoids or ACTH within two month prior to inclusion in the study.
- Has experienced a relapse within one month prior to the inclusion in the study.
- Has converted to secondary progressive MS.
- Has suffered from major depression or any other psychiatric disorder that would preclude safe participation in the protocol.
- Has diabetes mellitus.
- Has alcohol or drug abuse.
- Has cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV), or malignant hypertension.
- Has renal insufficiency.
- Has ASAT or ALAT > 2,5 x normal upper limit.
- Has leukopenia < 2500 leukocytes per µl or thrombocytopenia <100 000 thrombocytes per µl.
- Has any systemic disease, which can influence his/her safety and compliance, or the evaluation of the disability.
- Has thromboembolic disease that needs anticoagulative treatment.
- Have formerly shown severe reactions against study drug, interferon-beta or gadolinium (MRI contrast).
- Is breastfeeding or is pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
MRI disease activity measured by the number of new T1-enhancing lesions during the six months of treatment.
|
MRI disease activity measured by the number of new T1-hypo-intensive lesions (black holes) after 24 months of treatment.
|
Secondary Outcome Measures
Outcome Measure |
---|
MRI disease activity measured by the number of new T1-enhancing lesions during the first 9 months and the whole study period of 24 months.
|
Brain atrophy measured by total MRI brain volume at month 6 and month 24
|
The number of relapses during the first six months and the whole study period of 24 months.
|
The increase in disability as measured by Expanded Disability Status Scale (EDSS) during the first six months and the whole study period of 24 months.
|
Changes in the Multiple Sclerosis Functional Composite (MSFC) score during the first six months and the whole study period of 24 months.
|
MRI disease activity as measured by the number of new or enlarging T2 lesions and enhancing T1 lesions during the first six months and the whole study period of 24 months.
|
Changes in serum concentrations of mono-unsaturated fatty acids, saturated fatty acids, omega-3- and omega-6 fatty acids during the study.
|
Changes in immune responses during the first six months and the whole study period of 24 months.
|
The occurrence of adverse events during the first six months and the whole study period of 24 months.
|
The occurrence of adverse events during the first three months of interferon-beta 1a (Rebif®) treatment.
|
The occurrence of neutralising antibodies against interferon-beta 1a (Rebif®) during the study.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Kjell-Morten Myhr, MD, PhD, Dep. of Neurology, Haukeland University Hospital
- Principal Investigator: Antonie G. Beiske, MD, Dep. of Neurology, Akershus University Hospital
- Principal Investigator: Harald Hovdal, MD, Dep. of Neurology, Trondheim University Hospital
- Principal Investigator: Rune Midgard, MD, PhD, Dep. of Neurology, Molde Hospital
- Principal Investigator: Ingrid K. Bjørnå, MD, Dep. of Neurology, Buskerud Hospital
- Principal Investigator: Olaf A. Henriksen, MD, Dep. of Neurology Nordland Hospital
- Principal Investigator: Jan Schepel, MD, Dep. of Neurology Haugesund Hospital
- Principal Investigator: Randi Eikeland, MD, Dep. of Neurology Arendal Hospital
- Principal Investigator: Terje Kristensen, MD, Dep. of Neurology Fredrikstad Hospital
- Principal Investigator: Halfdan Kierulf, MD, Dep. of Neurology Rikshospitalet University Hospital
- Principal Investigator: Frøydis Dalane, MD, Dep. of Neurology, Telemark Hospital
- Principal Investigator: Alla Bru, MD, Dep. of Neurology, Stavanger University Hospital
- Principal Investigator: Grethe Kleveland, MD, Dep. of Neurology, Lillehammer Hospital
Publications and helpful links
General Publications
- Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000 Sep;102(3):143-9. doi: 10.1034/j.1600-0404.2000.102003143.x.
- Lie IA, Kerklingh E, Wesnes K, van Nederpelt DR, Brouwer I, Torkildsen O, Myhr KM, Barkhof F, Bo L, Vrenken H. The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. Eur Radiol. 2022 May;32(5):3576-3587. doi: 10.1007/s00330-021-08405-8. Epub 2022 Jan 3.
- Varhaug KN, Barro C, Bjornevik K, Myhr KM, Torkildsen O, Wergeland S, Bindoff LA, Kuhle J, Vedeler C. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.
- Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleas F, Pedersen T, Bjornara B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM. omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2012 Aug;69(8):1044-51. doi: 10.1001/archneurol.2012.283.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NSD-10842
- OFAMS, REK VEST, 005.04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing-Remitting Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on Triomar™ (omega-3 fatty acids)
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
S.LAB (SOLOWAYS)Center of New Medical Technologies; Triangel ScientificCompletedLDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II DiseaseRussian Federation
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
Wen-Chih WuWithdrawnSteatosis | Right Ventricular Failure | Pulmonary; HypertensionUnited States
-
University of California, San FranciscoAutism SpeaksCompleted
-
Tillotts Pharma AGCompletedCrohn's DiseaseUnited States, Canada
-
Pennington Biomedical Research CenterCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de Sousa, MD PhD; Pedro Emmanuel Alvarenga Americano do Brasil... and other collaboratorsCompletedChagas CardiomyopathyBrazil
-
Hugo W. Moser Research Institute at Kennedy Krieger...University of California, San FranciscoCompletedAutism Spectrum Disorders | HyperactivityUnited States
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States